Development of oral Pemetrexed prodrug aimed to improve QOL of the non-small cell lung cancer patients.

○Toru Otori

[27P02-237] Development of oral Pemetrexed prodrug aimed to improve QOL of the non-small cell lung cancer patients.

○Toru Otori¹, Tetutaro Kimachi², Tomohiro Maegawa¹, Akira Nakamura¹, Hyuji Ota¹, Takumi Nakata¹, Hideo Kobata¹, Yasuhiko Takata¹, Yume Obayashi¹, Yumi Sakai¹, Manabu Kitakoji¹, Mazuno Sumio¹, Kenji Matsuyama³ (1. Sch. Phar. Kindai Univ., 2. Sch. Phar. Mukogawa Univ., 3. I&H Holdings)

A password that applicants have been notified of is required to view abstracts.
If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts.
We will reply after confirming that you were a participant.
Thank you for your understanding.

Presentation information

[27P02] 医薬品適正使用
薬物療法（がん）
薬物療法（個別化）/医療薬学（その他）②

[27P02-237] Development of oral Pemetrexed prodrug aimed to improve QOL of the non-small cell lung cancer patients.

Password

Presentation information

[27P02] 医薬品適正使用薬物療法（がん）薬物療法（個別化）/医療薬学（その他）②

[27P02-237] Development of oral Pemetrexed prodrug aimed to improve QOL of the non-small cell lung cancer patients.

Password

[27P02] 医薬品適正使用
薬物療法（がん）
薬物療法（個別化）/医療薬学（その他）②